Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Molecular chaperones play important roles in preventing protein misfolding and its potentially harmful consequences. Deterioration of molecular chaperone systems upon ageing are thought to underlie age-related neurodegenerative diseases, and augmenting their activities could have therapeutic potential. The dementia relevant domain BRICHOS from the Bri2 protein shows qualitatively different chaperone activities depending on quaternary structure, and assembly of monomers into high-molecular weight oligomers reduces the ability to prevent neurotoxicity induced by the Alzheimer-associated amyloid-β peptide 1-42 (Aβ42). Here we design a Bri2 BRICHOS mutant (R221E) that forms stable monomers and selectively blocks a main source of toxic species during Aβ42 aggregation. Wild type Bri2 BRICHOS oligomers are partly disassembled into monomers in the presence of the R221E mutant, which leads to potentiated ability to prevent Aβ42 toxicity to neuronal network activity. These results suggest that the activity of endogenous molecular chaperones may be modulated to enhance anti-Aβ42 neurotoxic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the extracellular domain of BRI2 includes a BRICHOS domain that inhibits or delays Aβ aggregation (Chen et al, 2020; Tambaro et al, 2017).”
From Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias (2024) · cites this paper as Chen et al, 2020
In the citing paper
“BRI2 also has a dual anti-amyloidogenic function, reducing both Aβ production and Aβ aggregation.”
From Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias (2024) · cites this paper as Chen et al, 2020
In the citing paper
“a single point mutation, R221E, within the BRI2 BRICHOS domain has been shown to favor the monomeric form and exhibits greater efficacy than wild-type BRI2 BRICHOS in mitigating Aβ42-mediated neurotoxicity in mouse hippocampal slices (Chen et al, 2020; Manchanda et al, 2023).”
From Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias (2024) · cites this paper as Chen et al, 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
The proteostasis network and its decline in ageing
Hipp, M. S., Kasturi, P., & Hartl, F. U. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0101-y · Cited by 1,642
Gamma frequency entrainment attenuates amyloid load and modifies microglia
Iaccarino, H. F., Singer, A. C., Martorell, A. J., Rudenko, A., Gao, F., Gillingham, T. Z., Mathys, H., Seo, J., Kritskiy, O., Abdurrob, F., et al. (2016) · Nature · doi:10.1038/nature20587 · Cited by 1,328
Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition
Martorell, A. J., Paulson, A. L., Suk, H.-J., Abdurrob, F., Drummond, G. T., Guan, W., Young, J. Z., Kim, D. N.-W., Kritskiy, O., Barker, S. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.014 · Cited by 798
A stop-codon mutation in the BRI gene associated with familial British dementia
Vidal, R., Frangione, B., Rostagno, A., Mead, S., Révész, T., Plant, G., & Ghiso, J. (1999) · Nature · doi:10.1038/21637 · Cited by 466
Research works printed but not linked: 65
- Balchin, D., Hayer-Hartl, M. & Hartl, F. U. In vivo aspects of protein folding and quality control. Science 353, aac4354 (2016). · DOI · Paper page
- Soti, C. & Csermely, P. Aging and molecular chaperones. Exp. Gerontol. 38, 1037–40 (2003). · DOI · Paper page
- Wolff, S., Weissman, J. S. & Dillin, A. Differential scales of protein quality control. Cell 157, 52–64 (2014). · DOI · Paper page
- Shorter, J. Engineering therapeutic protein disaggregases. Mol. Biol. Cell 27, 1556–60 (2016). · DOI
- Aprile, F. A., Sormanni, P. & Vendruscolo, M. A rational design strategy for the selective activity enhancement of a molecular chaperone toward a target substrate. Biochemistry 54, 5103–12 (2015). · DOI
- Lindstedt, P. R. et al. Enhancement of the anti-aggregation activity of a molecular chaperone using a rationally designed post-translational modification. ACS Cent. Sci. 5, 1417–1424(2019). · DOI
- Sipe, J. D. et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23, 209–213 (2016). · DOI · Paper page
- Landreh, M. et al. The formation, function and regulation of amyloids: insights from structural biology. J. Intern. Med. 280, 164–76 (2016). · DOI
- Ankarcrona, M. et al. Current and future treatment of amyloid diseases. J. Intern. Med. 280, 177–202 (2016). · DOI
- Soejitno, A., Tjan, A. & Purwata, T. E. Alzheimer’s disease: lessons learned from amyloidocentric clinical trials. CNS Drugs 29, 487–502 (2015). · DOI
- Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016). · DOI · Paper page
- Meisl, G., Michaels, T. C. T., Linse, S. & Knowles, T. P. J. Kinetic analysis of amyloid formation. Methods Mol. Biol. 1779, 181–196 (2018). · doi:10.1007/978-1-4939-7816-8_12
- Cohen, S. I. et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl Acad. Sci. USA 110, 9758–63 (2013). · DOI · Paper page
- Arosio, P., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol. Sci. 35, 127–35 (2014). · DOI · Paper page
- Cohen, S. I. A. et al. A molecular chaperone breaks the catalytic cycle that generates toxic Abeta oligomers. Nat. Struct. Mol. Biol. 22, 207–213 (2015). · DOI · Paper page
- Wyatt, A. R., Yerbury, J. J., Ecroyd, H. & Wilson, M. R. Extracellular chaperones and proteostasis. Annu. Rev. Biochem. 82, 295–322 (2013). · DOI · Paper page
- Shammas, S. L. et al. Binding of the molecular chaperone alphaB-crystallin to Abeta amyloid fibrils inhibits fibril elongation. Biophys. J. 101, 1681–9 (2011). · DOI · Paper page
- Månsson, C. et al. Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (Abeta42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. J. Biol. Chem. 289, 31066–76 (2014). · DOI · Paper page
- Arosio, P. et al. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7, 10948 (2016). · DOI · Paper page
- Wilson, M. R. & Zoubeidi, A. Clusterin as a therapeutic target. Expert Opin. Ther. Targets 21, 201–213 (2017). · DOI · Paper page
- Bonito-Oliva, A., Barbash, S., Sakmar, T. P. & Graham, W. V. Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization. Sci. Rep. 7, 42880 (2017). · DOI
- Chen, G. et al. Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state. Nat. Commun. 8, 2081 (2017). · DOI · Paper page
- Poska, H. et al. Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits Abeta42 toxicity in Drosophila. Biochem. J. 473, 3683–3704 (2016). · DOI
- Hedlund, J., Johansson, J. & Persson, B. BRICHOS - a superfamily of multidomain proteins with diverse functions. BMC Res. Notes 2, 180 (2009). · DOI
- Sanchez-Pulido, L., Devos, D. & Valencia, A. BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem. Sci. 27, 329–32 (2002). · DOI · Paper page
- Willander, H. et al. High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. Proc. Natl Acad. Sci. USA 109, 2325–9 (2012). · DOI
- Knight, S. D., Presto, J., Linse, S. & Johansson, J. The BRICHOS domain, amyloid fibril formation, and their relationship. Biochemistry 52, 7523–31 (2013). · DOI
- Buxbaum, J. N. & Johansson, J. Transthyretin and BRICHOS: the paradox of amyloidogenic proteins with anti-amyloidogenic activity for Abeta in the central nervous system. Front. Neurosci. 11, 119 (2017). · DOI
- Oskarsson, M. E. et al. BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells. Proc. Natl Acad. Sci. USA 115, E2752–E2761 (2018). · DOI
- Willander, H. et al. BRICHOS domains efficiently delay fibrillation of amyloid beta-peptide. J. Biol. Chem. 287, 31608–17 (2012). · DOI
- Nerelius, C., Gustafsson, M., Nordling, K., Larsson, A. & Johansson, J. Anti-amyloid activity of the C-terminal domain of proSP-C against amyloid beta-peptide and medin. Biochemistry 48, 3778–86 (2009). · DOI
- Akiyama, H. et al. Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol. 107, 53–8 (2004). · DOI
- Del Campo, M. et al. BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer’s disease. Neurobiol. Aging 35, 1596–604 (2014). · DOI
- Dolfe, L. et al. The Bri2 and Bri3 BRICHOS Domains Interact Differently with Abeta42 and Alzheimer Amyloid Plaques. J. Alzheimers Dis. Rep. 2, 27–39 (2018). · DOI
- Martin, L. et al. Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/SPPL2b. J. Biol. Chem. 283, 1644–52 (2008). · DOI · Paper page
- Kronqvist, N. et al. Efficient protein production inspired by how spiders make silk. Nat. Commun. 8, 15504 (2017). · DOI
- Sarr, M. et al. A spidroin-derived solubility tag enables controlled aggregation of a designed amyloid protein. FEBS J. 285, 1873–1885 (2018). · DOI
- Buzsaki, G. Rhythms of the Brain. (Oxford Univ. Press, Oxford, 2006). · DOI · Paper page
- Yamamoto, J., Suh, J., Takeuchi, D. & Tonegawa, S. Successful execution of working memory linked to synchronized high-frequency gamma oscillations. Cell 157, 845–57 (2014). · DOI · Paper page
- Ribary, U. et al. Magnetic field tomography of coherent thalamocortical 40-Hz oscillations in humans. Proc. Natl Acad. Sci. USA 88, 11037–41 (1991). · DOI · Paper page
- Tambaro, S. et al. Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice. J. Biol. Chem. 294, 2606–2615 (2019). · DOI
- Khurana, R. et al. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol. 151, 229–38 (2005). · DOI · Paper page
- Cohen, S. I. A., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. J. From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 421, 160–171 (2012). · DOI · Paper page
- Knowles, T. P. J. et al. An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533–1537 (2009). · DOI · Paper page
- Cohen, S. I. A. et al. Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. J. Chem. Phys. 135, 065105 (2011). · DOI · Paper page
- Cohen, S. I. A., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. J. Nucleated polymerization with secondary pathways. II. Determination of self-consistent solutions to growth processes described by non-linear master equations. J. Chem. Phys. 135, 065106 (2011). · DOI · Paper page
- Limbocker, R. et al. Trodusquemine enhances Abeta42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nat. Commun. 10, 225 (2019). · DOI
- Mannini, B. et al. Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. Proc. Natl Acad. Sci. USA 109, 12479–84 (2012). · DOI · Paper page
- Walti, M. A. et al. Atomic-resolution structure of a disease-relevant Abeta(1-42) amyloid fibril. Proc. Natl Acad. Sci. USA 113, E4976–84 (2016). · DOI · Paper page
- Colvin, M. T. et al. Atomic resolution structure of monomorphic Abeta42 amyloid fibrils. J. Am. Chem. Soc. 138, 9663–74 (2016). · DOI · Paper page
- Scheidt, T. et al. Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-beta aggregates. Sci. Adv. 5, eaau3112 (2019). · DOI · Paper page
- Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188–203 (2012). · DOI · Paper page
- Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537–49 (2010). · DOI · Paper page
- Nagaraj, R. H. et al. Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. Biochemistry 42, 10746–55 (2003). · DOI
- Srinivas, V., Raman, B., Rao, K. S., Ramakrishna, T. & Rao, Ch,M. Structural perturbation and enhancement of the chaperone-like activity of alpha-crystallin by arginine hydrochloride. Protein Sci. 12, 1262–70 (2003). · doi:10.1110/ps.0302003
- Bongiovanni, M. N., Aprile, F. A., Sormanni, P. & Vendruscolo, M. A rationally designed Hsp70 variant rescues the aggregation-associated toxicity of human IAPP in cultured pancreatic islet beta-cells. Int. J. Mol. Sci. 19, 1443 (2018). · DOI
- Haslbeck, M., Weinkauf, S. & Buchner, J. Small heat shock proteins: simplicity meets complexity. J. Biol. Chem. 294, 2121–2132 (2019). · DOI · Paper page
- Lelj-Garolla, B. & Mauk, A. G. Self-association and chaperone activity of Hsp27 are thermally activated. J. Biol. Chem. 281, 8169–74 (2006). · doi:10.1074/jbc.m512553200
- Gupta, R. & Srivastava, O. P. Deamidation affects structural and functional properties of human alphaA-crystallin and its oligomerization with alphaB-crystallin. J. Biol. Chem. 279, 44258–69 (2004). · doi:10.1074/jbc.m405648200
- Benesch, J. L., Ayoub, M., Robinson, C. V. & Aquilina, J. A. Small heat shock protein activity is regulated by variable oligomeric substructure. J. Biol. Chem. 283, 28513–7 (2008). · DOI
- Liu, Z. et al. Mechanistic insights into the switch of alphaB-crystallin chaperone activity and self-multimerization. J. Biol. Chem. 293, 14880–14890 (2018). · DOI
- Peschek, J. et al. Regulated structural transitions unleash the chaperone activity of alphaB-crystallin. Proc. Natl Acad. Sci. USA 110, E3780-9 (2013). · DOI · Paper page
- Lee, J. T. et al. Enhancement of the chaperone activity of alkyl hydroperoxide reductase C from pseudomonas aeruginosa PAO1 resulting from a point-specific mutation confers heat tolerance in Escherichia coli. Mol. Cells 39, 594–602 (2016). · doi:10.14348/molcells.2016.0042
- Abelein, A., Gräslund, A. & Danielsson, J. Zinc as chaperone-mimicking agent for retardation of amyloid β peptide fibril formation. Proc. Natl Acad. S. USA 112, 5407–5412 (2015). · DOI · Paper page
- Abelein, A., Jarvet, J., Barth, A., Gräslund, A. & Danielsson, J. Ionic strength modulation of the free energy landscape of Aβ40 peptide fibril formation. J. Am. Chem. Soc. 138, 6893–6902 (2016). · DOI
Cited by
Abelein, A., Ciofi-Baffoni, S., Mörman, C., Kumar, R., Giachetti, A., Piccioli, M., & Biverstål, H. (2022) · JACS Au · doi:10.1021/jacsau.2c00438 · Cited by 52
Self-citationFunctional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias
Yin, T., Yesiltepe, M., & D’Adamio, L. (2024) · EMBO Reports · doi:10.1038/s44319-024-00077-x · Cited by 15
Metadata
- Authors
- Chen, G., Andrade-Talavera, Y., Tambaro, S., Leppert, A., Nilsson, H. E., Zhong, X., Landreh, M., Nilsson, P., Hebert, H., Biverstål, H., Fisahn, A., Abelein, A., & Johansson, J.
- ORCID
- Venue
- Communications Biology
- Published
- 2020-01-20
- Volume
- 3
- Issue
- 1
- ISSN
- 2399-3642
- Cited by
- 61
- References
- 9
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Vetenskapsrådet (2016-01967)
- VINNOVA (2016-04059)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro. https://app.cochat.ai/papers/10.1038/s42003-020-0757-z
- The paper
- Chen, G., Andrade-Talavera, Y., Tambaro, S., Leppert, A., Nilsson, H. E., Zhong, X., Landreh, M., Nilsson, P., Hebert, H., Biverstål, H., Fisahn, A., Abelein, A., & Johansson, J. (2020). Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro. Communications Biology. https://doi.org/10.1038/s42003-020-0757-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.